Update re disposal of 80% of Mankayan Project
NMC Health
938.40p
16:44 27/04/20
13 November 2019
Bezant Resources Plc
("Bezant" or the "Company")
Satisfaction of all Conditions Precedent re Disposal of 80% of the Company's interest in the Mankayan Copper-Gold project, Philippines, to MMIH (Singapore)
Bezant (AIM: BZT), the copper-gold exploration and development company, is pleased to announce, further to its announcement of 30 October 2019, that all of the Conditions Precedent have been satisfied in relation to the disposal of 80% of the Company's interest in the Mankayan Copper-Gold project, Philippines, to Mining and Minerals Industries Holding Pte. Ltd. (the "Transaction"). Accordingly, the requisite legal documentation is now being finalised to enable the issue of shares in Asean Copper Investments Limited to MMJV pursuant to the terms the Transaction Agreement, and a further announcement will be released in due course to confirm completion of the Transaction.
Full details of the Transaction are set out in the Company's announcement of 7 October 2019 and circular dated 11 October 2019, as sent to shareholders and made available on the Company's website.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings given to them in the circular dated11 October 2019.
For further information, please contact:
Bezant Resources plc Laurence Read Chief Executive Officer
Colin Bird Executive Chairman
Strand Hanson Limited (Nomad) James Harris / Matthew Chandler / James Bellman
Novum Securities Limited (Broker) Jon Belliss
or visit http://www.bezantresources.com |
Tel: +44 (0)20 3289 9923
Tel: +44 (0)20 7409 3494
Tel: +44 (0)20 7399 9400 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.